NX-13

NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis[1][2].

Signaling Pathways >> Immunology/Inflammation >> NOD-like Receptor (NLR)

Research Areas >> Inflammation/Immunology

NLRX1

NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels[2]. NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract[2]. Animal Model: Sprague Dawley rats (six weeks age)[2] Dosage: 0, 500, or 1000 mg/kg Administration: Oral gavage; 7 days Result: ALP in rats given the 1000 mg/kg dose level was lower than that in rats given 500 mg/kg. Animal Model: Male C57BL/6J mice (8-10 weeks age)[2] Dosage: 1 and 10 mg/kg (Pharmacokinetics analysis) Administration: Oral gavage; 24 hours Result: Reached the distal gastrointestinal tract.

[1]. Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203(12):3407-3415.

[2]. Leber A, et.al. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1 [published online ahead of print, 2019 Oct 25]. Drug Chem Toxicol. 2019;1-6.